Inlyta

axitinib · Pfizer Europe MA EEIG
AUTHORISED IN THE EU

What Inlyta is used for

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Inlyta
Active substance
axitinib
Disease area
Carcinoma, Renal Cell
Medicine group
Protein kinase inhibitors
ATC code
L01EK01
Marketing authorisation holder
Pfizer Europe MA EEIG
Authorised in the EU since
2012

Official information

In the USA

Same active substance: Inlyta

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Inlyta used for?

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

What is the active substance in Inlyta?

Inlyta contains axitinib.

Who makes Inlyta?

The EU marketing authorisation holder is Pfizer Europe MA EEIG.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.